Astra Zeneca’s long-acting COVID-19 antibody (AZD7442) advances into phase III development

Two phase III clinical trials are to begin enrolment in the next few weeks; one will assess safety and efficacy to prevent infection for up to 12 months (n= 5,000) and the second will evaluate post-exposure prophylaxis and pre-emptive treatment (n= 1,100).

Source:

PharmaTimes